Ximbio (www.ximbio.com), an online reagents portal for the life science community, which originates from Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK, has increased the number of reagents in its portfolio by 42% since the website launched in October last year. The company now has more than 20 research institutes from the UK, Europe and the USA enlisted to virtually deposit their reagents.
Ximbio provides a portal for the life science community to exchange knowledge and trade reagents. Researchers and technology transfer offices can virtually upload their reagents to the Ximbio website. Bench scientists can make informed decisions about which reagents to use via the Ximbio searchable database, extensive datasheets, peer reviews and supplier options. Each reagent record can be linked to the originating inventor, enabling scientists and institutions to raise the profile of their work.
All reagents listed on Ximbio are supported with originating data on the generation and validation of the tool. There are now more than 2500 peer-reviewed references, linked to 1401 reagents, which are accessible to every user.
“In recent months, we have seen an increased awareness across the research community for the need for data reproducibility. Scientists are becoming more critical of the antibodies and other reagents they are using, and access to characterization data is something that more researchers are asking for. At Ximbio, we are committed to both antibody reproducibility and open source information, which is why we ensure all new reagents listed on the website have supporting data or a peer reviewed journal showing how the tool was created or validated,” commented Melanie Hardman, Head of Ximbio.
Life science companies can use Ximbio to easily source new products to augment their portfolios via a straightforward commercialisation process. The company has a global reach, with more than 200 suppliers and biotech companies licensing products through Ximbio, from the US, Europe, Asia and Australia.